You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
ARC 239 dihydrochloride
Selective α2B adrenoceptor antagonist (pKD values are 8.8, 6.7 and 6.4 at α2B, α2A, and α2D receptors respectively). Also available as part of the α2-Adrenoceptor Tocriset™.
Sold with the permission of Boehringer Ingelheim GmbH
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 480.43. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.08 mL||10.41 mL||20.81 mL|
|5 mM||0.42 mL||2.08 mL||4.16 mL|
|10 mM||0.21 mL||1.04 mL||2.08 mL|
|50 mM||0.04 mL||0.21 mL||0.42 mL|
References are publications that support the biological activity of the product.
Bylund et al (1988) Alpha-2A and alpha-2B adrenergic subtypes: antagonist binding in tissues and cell lines containing only one subtype. J.Pharmacol.Exp.Ther. 245 600 PMID: 2835476
Fuder and Selback (1993) Characterisation of sensory neurotransmission and its inhibition via α2B-adrenoceptors and via non-α2 adrenoceptors in rabbit iris. Naunyn Schmiedebergs Arch.Pharmacol. 347 394 PMID: 7685502
If you know of a relevant reference for ARC 239 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: ARC 239 dihydrochloride, ARC 239 dihydrochloride supplier, α2B-adrenoceptor, alpha2B-adrenoceptor, α2b-adrenergic, alpha2b-adrenergic, a2b-adrenoceptor, a2b-adrenergic, antagonists, Receptors, ARC239, dihydrochloride, Adrenergic, Alpha-2, 0928, Tocris Bioscience
1 Citation for ARC 239 dihydrochloride
Citations are publications that use Tocris products. Selected citations for ARC 239 dihydrochloride include:
Kahn et al (2016) The anti-hypertensive drug pra. inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway. EMBO Mol Med 8 511 PMID: 27138566
Do you know of a great paper that uses ARC 239 dihydrochloride from Tocris? Please let us know.
Reviews for ARC 239 dihydrochloride
There are currently no reviews for this product. Be the first to review ARC 239 dihydrochloride and earn rewards!
Have you used ARC 239 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.